注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Alpine Immune Sciences Inc是一家生物制药公司。该公司致力于发现和开发基于蛋白质的免疫疗法,以治疗癌症、自身免疫和炎症性疾病。该公司的科学平台使用定向进化过程将免疫球蛋白超家族(IgSF)的天然免疫系统蛋白转化为能够调节人类免疫系统的多靶点疗法。其候选产品包括ALPN-101、ALPN-202和ALPN-303。ALPN-101是一种双重诱导型T细胞共刺激剂(ICOS)和分化簇28(CD28)拮抗剂,旨在治疗自身免疫性疾病和炎症性疾病。其肿瘤学项目是ALPN-202,一种用于治疗癌症的条件性CD28共刺激剂和双重检查点抑制剂。ALPN-303是一种双重B细胞细胞因子拮抗剂,用于治疗B细胞介导的疾病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Peter A. Thompson | 61 | 2016 | Independent Director |
Andrew M. Scharenberg | - | - | Scientific Advisory Board Chairman |
Robert E. Conway | 67 | 2017 | Independent Director |
Mitchell H. Gold | 53 | 2015 | Executive Chairman & CEO |
James N. Topper | 59 | 2016 | Independent Director |
Paul Tumeh | - | - | Member of Scientific Advisory Board |
Manish J. Butte | - | - | Member of Scientific Advisory Board |
Xiangmin Cui | 55 | 2019 | Independent Director |
John A. Thompson | - | 2018 | Member of Scientific Advisory Board |
Anne Davidson | - | - | Member of Scientific Advisory Board |
Christopher Peetz | 44 | 2018 | Independent Director |
Vijay Kumar Kuchroo | 68 | 2019 | Member of Scientific Advisory Board |
James Welsh | - | 2018 | Member of Scientific Advisory Board |
Rafi Ahmed | - | 2018 | Member of Scientific Advisory Board |
Natasha A. Hernday | 51 | 2020 | Independent Director |
Jorn Drappa | 58 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核